stockrowPluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025.
- Revenue
- −15.8%
- EPS
- +44.8%
- Free cash flow
- +25.0%
- Total debt
- +3.43%
Quarter to June 2026, against a year earlier
Follow PLUR
Alert me
Pluri Inc. (PLUR) Piotroski F-score
Pluri Inc.'s Piotroski F-score for fiscal 2026 is 1 out of 9: 1 of nine tests of profitability, leverage and efficiency passed, down from 3 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 1 | (2.00) |
| FY2025 | 3 | (1.00) |
| FY2024 | 4 | 0.00 |
| FY2020 | 4 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (74.95%) | (57.75%) | Fail | 0 |
| Positive operating cash flow | (19.59m) | (18.21m) | Fail | 0 |
| Rising return on assets | (74.95%) | (57.75%) | Fail | 0 |
| Cash flow above net income | 4.23m | 4.37m | Pass | 1 |
| Falling long-term leverage | 0.02 | 0.00 | Fail | 0 |
| Rising current ratio | 0.27 | 0.68 | Fail | 0 |
| No new shares issued | 9,744,000 | 6,337,000 | Fail | 0 |
| Rising gross margin | 44.59% | 48.95% | Fail | 0 |
| Rising asset turnover | 0.03 | 0.03 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 1 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| KYNB Kyntra Bio Inc compare | 5 |
| ADAPY Adaptimmune Therapeutics PLC compare | 4 |
| MRKR MARKER THERAPEUTICS, INC. compare | 3 |
| ATYR aTyr Pharma, Inc. compare | 2 |
| PLUR Pluri Inc. | 1 |
| NEUP Neuphoria Therapeutics Inc. compare | — |
| VAXX Vaxxinity, Inc. compare | — |
| CTXR Citius Pharmaceuticals, Inc. compare | — |
| ABOS Acumen Pharmaceuticals, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover